in cardiovascular medicine
Alkaline phosphatase, but not serum phosphate, associated with increased CV risk
Alkaline Phosphatase, Serum Phosphate, and Incident Cardiovascular Disease and Total Mortality in Older Men.
Wannamethee SG, Sattar N, Papcosta O et al
Arterioscler Thromb Vasc Biol. 2013 Feb 21.
End-stage renal disease often comes with altered mineral metabolism such as changes in alkaline phosphatase (ALP) and circulating phosphate concentrations [1-3]. Several studies have linked elevated circulating phosphate levels and serum ALP levels to increased coronary calcification and cardiovascular risk in persons with chronic kidney disease [1-4]. Also for the general population serum phosphate has been described to be associated with increased risk of cardiovascular disease (CVD) [5-9]. However, some studies did not find an association between phosphate and coronary heart disease (CHD) events in the general population [7,8,10]. Population studies that looked at ALP and CVD, found a that increased levels are associated with increased CVD mortality and hospitalization [11-13]. ALP is associated with a marker of inflammation , but the role of inflammation in the relationship between ALP and CVD is unclear.
This prospective study investigated the association between serum phosphatase and ALP with CHD risk, stroke, CVD mortality and total mortality, in 3381 men aged 60 to 79 year, without a history of myocardial infarction or stroke.
High ALP was significantly associated with increased risk of major CHD events and CVD events and CVD mortality, which could partly be explained by CV risk factors and inflammation.
Serum phosphatise was only significantly associated with CVD mortality not due to CHD or stroke (HR:1.35 [1.01, 1.83]; P=0.04), but showed no associations with CHD or stroke risks.
ALP and serum phosphate were both associated with increased total mortality, even after adjustment for inflammation and exclusion of men with chronic kidney disease.
This study confirms some earlier findings on the associations of ALP and phosphate with CHD/CVD events and total mortality, and extends these findings to older men without CVD. The authors discuss the potential contribution of inflammation, but further research is needed to elucidate the nature of the association between ALP and phosphate with CHD and CVD outcomes.
1.Covic A, Kothawala P, Bernal M, Robbins S, Chalian A, Goldsmith D. Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol Dial Transplant. 2009;24:1506–1523.
2. Palmer SC, Hayen A, Macaskill P, Pellegrini F, Craig JC, Elder GJ, Strippoli GF. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with
chronic kidney disease: a systematic review and meta-analysis. JAMA.2011;305:1119–1127.
3. Regidor DL, Kovesdy CP, Mehrotra R, Rambod M, Jing J, McAllister CJ, Van Wyck D, Kopple JD, Kalantar-Zadeh K. Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients. J
Am Soc Nephrol. 2008;19:2193–2203.
4. Adeney KL, Siscovick DS, Ix JH, Seliger SL, Shlipak MG, Jenny NS, Kestenbaum BR. Association of serum phosphate with vascular and valvular calcification in moderate CKD. J Am Soc Nephrol. 2009;20:381–387.
6 Larsson TE, Olauson H, Hagström E, Ingelsson E, Arnlöv J, Lind L, Sundström J. Conjoint effects of serum calcium and phosphate on risk of total, cardiovascular, and noncardiovascular mortality in the community.
Arterioscler Thromb Vasc Biol. 2010;30:333–339.
7. Foley RN, Collins AJ, Ishani A, Kalra PA. Calcium-phosphate levels and cardiovascular disease in community-dwelling adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J. 2008;156:556–563.
8. Onufrak SJ, Bellasi A, Cardarelli F, Vaccarino V, Muntner P, Shaw LJ, Raggi P. Investigation of gender heterogeneity in the associations of serum phosphorus with incident coronary artery disease and all-cause
mortality. Am J Epidemiol. 2009;169:67–77.
9. Dhingra R, Sullivan LM, Fox CS, Wang TJ, D’Agostino RB Sr, Gaziano JM, Vasan RS. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med.
10. Slinin Y, Blackwell T, Ishani A, Cummings SR, Ensrud KE; and for the MORE Investigators. Serum calcium, phosphorous and cardiovascular events in post-menopausal women. Int J cardiol 2011;149:335–340.
11.Tonelli M, Curhan G, Pfeffer M, Sacks F, Thadhani R, Melamed ML, Wiebe N, Muntner P. Relation between alkaline phosphatase, serum phosphate, and all-cause or cardiovascular mortality. Circulation. 2009;120:
12. Ryu WS, Lee SH, Kim CK, Kim BJ, Yoon BW. Increased serum alkaline phosphatase as a predictor of long-term mortality after stroke.Neurology. 2010;75:1995–2002.
13. Abramowitz M, Muntner P, Coco M, Southern W, Lotwin I, Hostetter TH, Melamed ML. Serum alkaline phosphatase and phosphate and risk of mortality and hospitalization. Clin J Am Soc Nephrol. 2010;5:1064–1071.
14.Webber M, Krishnan A, Thomas NG, Cheung BM. Association between serum alkaline phosphatase and C-reactive protein in the United States National Health and Nutrition Examination Survey 2005–2006. Clin
Chem Lab Med. 2010;48:167–173.
We have examined the association between serum phosphate and alkaline phosphatase (ALP) with incident cardiovascular disease (CVD) outcomes and total mortality in older men.
Approach and Results
A prospective study of 3381 men, aged 60 to 79 years, without a history of myocardial infarction or stroke followed up for an average 11 years during which there were 605 major CVD events (fatal coronary heart disease and nonfatal myocardial infarction, stroke, and CVD death) and 984 total deaths. ALP but not serum phosphate was associated with increased risk of coronary heart disease and overall CVD events which persisted after adjustment for CVD risk factors and markers of inflammation and after exclusion of men with chronic kidney disease (adjusted hazard ratio per SD, 1.19 [1.05, 1.34]; P=0.007 and 1.10 [1.01, 1.21]; P=0.04). In contrast, serum phosphate was only associated with increased CVD mortality owing to noncoronary heart disease or stroke causes (adjusted hazard ratio per SD, 1.35 [1.01, 1.83]; P=0.04). Both raised phosphate and ALP were associated with significantly increased total mortality after full adjustment and exclusion of men with chronic kidney disease.
ALP but not serum phosphate is associated with coronary heart disease risk in elderly men. High levels of ALP and serum phosphate are both associated with increased total mortality.
Stark decline in mortality due to coronary heart disease in Europe since early 1980s
In many countries CHD mortality has reduced by almost half, but large differences exist between countries.
Effect of statin and exercise on mortality
5-12-2012 • Kokkinos PF. et al. Lancet 2012; DOI:10.1016/S0140-6736(12)61426-3
Lancet, Nov 2012
. Combined effects of fitness and statin treatment on all-cause mortality assessed in prospective cohort study. Statin treatment and exercise lowers mortality risk substantially more than either alone.
Gender-related differences in short- and long-term mortality after MI
4-10-2012 • Nauta ST et al, Circulation. 2012 Sep 24.
Adjusted mortality rates for both men and women similar and declined markedly over a 24-year period. Both sexes seem to benefit from evidence-based therapies that have been developed and implemented during this time period.
Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis
Chronic kidney disease (CKD) is a potent independent risk factor for cardiovascular disease (CVD). Non-traditional risk factors such as vascular calcification (VC) contribute to the significantly increased rates of cardiovascular events and mortality in CKD.
Hyperphosphatemia of Chronic Kidney Disease
Observational studies have determined hyperphosphatemia to be a cardiovascular risk factor in chronic kidney disease. Mechanistic studies have elucidated that hyperphosphatemia is a direct stimulus to vascular calcification, which is one cause of morbid cardiovascular events contributing to the excess mortality of chronic kidney disease. This review describes the pathobiology of hyperphosphatemia that develops as a consequence of positive phosphate balance in chronic kidney disease and the mechanisms by which hyperphosphatemia acts on neointimal vascular cells that are stimulated to mineralize in chronic kidney disease. The characterization of hyperphosphatemia of chronic kidney disease as a distinct syndrome in clinical medicine with unique disordered skeletal remodeling, heterotopic mineralization and cardiovascular morbidity is presented.
Depression in heart failure patients associated with 5-fold increased mortality risk
Moderate to severe depression is strongly associated with death during the year following discharge after admission for exacerbation of heart failure, irrespective of the severity of heart failure or the presence of comorbidities.
Causal link between triglycerides and coronary heart disease, but role for HDL-c less clear
11-3-2015 • Holmes MV Eur Heart J. 2015
Large Mendelian randomisation approach provides support for a causal role of tryglycerides in the development of CHD events. Such a causal link between HDL-c and CHD remains uncertain.
CETP inhibition alters lipid profile in dyslipidaemic subjects and in CHD patients
18-2-2015 • J Clin Lipidol. 2015
The CETP-inhibitor anacetrapib changes levels of different LDL particle subfractions. In another study, anacetrapib's lipid-modifying effect was generally consistent across subgroups of CHD patients.
Inactivating mutations in gut cholesterol transporter lower LDL-c levels and CHD risk
18-11-2014 • The Myocardial Infarction Genetics Consortium Investigators, NEJM 2014
15 mutations identified in the Niemann-Pick C1-like gene were underrepresented in patients with coronary heart disease. Lifelong activation of one
-allele seems protective against CHD.
Prof. dr. Freek Verheugt: “Role of aspirin in cancer mortality far from clear”
Prof. dr. F.W.A. Verheugt (Amsterdam) responds to an article in Ann Oncol of this week about the effect of prophylactic aspirin use with regard to cancer and CVD events.
Many chronic inflammatory disorders associated with higher risk of CHD and diabetes
2-7-2014 • Dregan A et al., Circulation. 2014
Population-based study shows that diverse chronic inflammatory disorders were associated with an increased risk of at least two of the CHD, stroke and diabetes outcomes, possibly in a dose-responsive fashion.
Stressful life events and social strain associated with higher incident CHD and stroke
1-7-2014 • Kershaw KN et al., J Am Heart Assoc. 2014
The Women’s Health Initiative observational study showed that these associations were explained by mediating behavioural and biological factors. Insights can help target stress management strategies.
© 2009 - 2015 PACE - Physicians's Academy for Continuing Education -